As oligo manufacturers scale up production from lab-scale to clinical and commercial scales, they may require volumes of hazardous materials that drive additional facility design considerations.
Bill Jarvis
Advertisement
Bill Jarvis is senior fellow, Pharmaceutical Process, at CRB.
Articles by Bill Jarvis
Advertisement
Latest Updated Articles
Oligonucleotide Production FacilitiesPublished: November 15th 2023 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Strategic Shifts for Speed, Resilience, and Long-Term Sustainability in Biomanufacturing
2
Why Data Quality, Not Regulation, Is the True Barrier to AI in Biologics
3
RNAnalytics CPHI Interview, Part Two: Nanoparticle Case Studies and Response to US mRNA Pullback
4
How Is AI Transforming Biomanufacturing and Biopharma Workforce Training?
5
